

Table S2 – Plasma levels of 64 cytokines and 13 soluble receptors from active (aBD) and inactive Behçet’s disease (iBD) patients and healthy controls (HC) determined by addressable laser bead immunoassay.

Cytokines ^a (pg/mL)	HC (n=30)	iBD (n=31)	aBD (n=30)	p- value
sCD40L	47.45/33.68–26,743.00	17,234.00/2,346.00–19,279.00	18,288.50/412.58–19,883.00	<0.01
IL1α	17.75/12.24–122.95	23.81/14.38–147.36	20.66/10.59–96.33	NS
IL1β	2.54/1.54–6.70	4.13/1.94–20.50♦	0/0–20.33¶	<0.01
IL-1Ra	46.87/34.31 – 121.51	63.63/47.01 – 297.79*	62.00/41.30 – 297.19*	<0.01
sIL1-RI	29.20/20.72 – 138.72	44.32/0 – 213.99	35.47/0 – 260.86	NS
sIL1-RII	5520.64±2532.45¶	9369.78±4212.03*♦	5823.89±1855.61¶	<0.01
IL2	3.18/1.94–8.87¶	4.27/2.53–25.85*♦	2.61/0–29.33¶	<0.01
sIL2-Ra	991.47±465.06	1459.92±818.41	1297.84±521.24	NS
IL3	1.40/0–5.33	1.70/1.38–9.84♦	0/0–7.12¶	<0.01
IL4	13.80/9.96–353.44	20.29/11.67–80.18	18.17/8.14–144.49	NS
sIL4-R	159.86/57.13 – 354.93¶	501.85/158.97 – 1512.99*♦	203.26/86.16 – 548.21¶	<0.01
IL5	3.08/1.80–11.02¶	4.25/2.24–27.18*♦	1.08/0–15.05¶	<0.01
IL6	4.10/2.59–8.61¶	8.51/4.29–137.24*♦	5.95/2.38–45.80¶	<0.01
sIL6-R	10526.05/4593.32 – 27412.50¶	18122.82/0 – 200000.76*	13179.64/0 – 150969.32	<0.05
IL7	4.55±2.53¶	9.79±6.56*♦	4.30±3.71¶	<0.01
IL8	10.65/2.91–136.50	14.20/5.01–57.97	18.73/1.31–281.36	NS
IL9	2.34/1.23–9.81¶	3.74/2.42–10.64*♦	0.77/0–11.23¶	<0.01
IL10	9.78/7.48–30.68¶	15.98/11.63–358.12*♦	10.99/6.24–60.19¶	<0.01
IL-12p40	17.01±6.58	35.13±15.01*	37.36±20.75*	<0.01
IL-12p70	9.86/6.39–76.36	13.25/8.31–319.10	9.98/6.69–256.30	NS
IL13	4.28/2.77–30.67¶	7.40/3.74–43.08*♦	4.50/1.28–20.41¶	<0.01
IL15	6.79±1.92¶	10.41±4.13*♦	7.01±3.30¶	<0.01
IL16	51.44±38.06	70.19±35.37	68.83±27.41	NS
IL17	6.17/2.98–75.56♦	7.49/3.42–200.11♦	3.92/0–542.35*¶	<0.01
IL20	26.62/0–181.59♦	30.37/0–86.35♦	51.49/24.16–88.18*¶	<0.01

Cytokines^a (pg/mL)	HC (n=30)	iBD (n=31)	aBD (n=30)	p-value
IL21	7.24/5.30–27.80♦	7.75/0–146.50♦	9.39/7.51–31.76*¶	<0.01
IL23	178.00/104.21–629.40	177.45/106.82–4275.00	197.70/123.78–998.14	NS
IL28A	47.10/36.89–469.58	51.86/35.10–225.38	55.17/42.30–222.10	NS
IL33	11.78/0–52.90	12.57/0–384.81	12.27/0–115.77	NS
TNFα	6.88/3.28 – 17.01	14.14/6.00 – 45.36*	11.57/0.00 – 45.28*	<0.01
TNFβ	11.34/8.65–847.32	10.94/8.16–71.00	9.12/5.22–34.27	NS
sTNFR1	761.68±292.31	1139.27±414.94*	1232.20±414.36*	<0.01
sTNFR2	5434.61±1836.53	9997.32±4738.43*	9761.44±6254.79*	<0.01
TGFα	3.42/0–11.09	3.84/0–38.37	5.11/0–17.73	NS
IFNα	20.15/14.83 – 69.73	39.93/16.41 – 166.58*	42.67/24.66 – 132.68*	<0.01
IFNγ	8.79/5.81 – 40.73	14.31/6.90 – 155.96*	17.97/5.31 – 198.54*	<0.01
IP10	168.49/48.16 – 621.48	532.99/199.27 – 1642.00*	372.38/128.66 – 3729.00*	<0.01
MIP1α	10.13/4.69 – 39.15	11.09/4.33 – 119.89♦	22.12/10.92 – 193.19*¶	<0.01
MIP1β	16.26/6.34 – 42.36	23.74/8.58 – 146.82*	26.38/12.00 – 88.63*	<0.01
MIP1Δ	3649.00/774.24–18757	3796.00/543.59–10174	3429.00/196.72–19369	NS
Eotaxin-1	21.05/14.31 – 626.10	417.27/22.15 – 1546.00*	341.92/39.13 – 1340.00*	<0.01
Eotaxin-2	763.87/155.49 – 5681.00	242.06/46.82 – 1463.00*	236.07/81.46 – 2108.00*	<0.01
Eotaxin-3	52.47/0–159.78	58.83/0–179.88	57.05/26.78–196.30	NS
BCA-1	11.97/5.65 – 54.49	25.34/14.03 – 2210.00*	38.00/18.63 – 309.40*	<0.01
CTACK	243.16/51.19 – 1123.00	608.99/208.13 – 976.66*	694.43/287.05 – 1304.00*	<0.01
RANTES	14206.96±4453.02	8845.67±2569.96*	9127.13±3743.69*	<0.01
TRAIL	53.40±22.86	64.47±22.19	55.44±21.97	NS
FGF	64.98/51.31 – 142.43	81.78/60.28 – 1147.00*	86.43/60.83 – 317.37*	<0.01
G-CSF	58.23/40.37 – 165.64	74.64/47.63 – 314.22*	67.76/46.24 – 967.36*	<0.01
EGF	86.23/20.27 – 878.41	41.94/18.01 – 243.74*	40.29/17.84 – 227.78*	<0.01
GM-CSF	17.59/11.92–44.56	19.83/14.61–142.31	15.53/8.34–104.87	NS
PDGF-AA	1836.50/282.16–5825	1539.00/539.50–4268	1273.50/134.45–4527	NS

Cytokines^a (pg/mL)	HC (n=30)	iBD (n=31)	aBD (n=30)	p-value
PDGF-AB/BB	8290.40/2194–17759	8974.00/1340–20905	9372.00/1150–21857	NS
SCF	34.85/23.74–75.72	42.66/28.19–153.67	40.56/22.04–77.87	NS
VEGF	205.17/134.60–440.13	207.61/148.52–1923.00	213.72/131.10–3376.00	NS
sVEGFR1	336.22/96.03 – 862.13	1724.85/0.00 – 4154.77*	1857.94/99.30 – 3740.25*	<0.01
sVEGFR2	19676.71/13388.11 – 27752.86¶	26774.39/15764.65 – 104368.35*♦	21205.25/8240.85– 98000.73¶	<0.01
sVEGFR3	194.62/29.73 – 1173.59	588.47/0.00 – 3385.05*	609.44/20.03 – 2671.95*	<0.01
Thrombopoietin	418.24/227.48–882.36	347.28/242.92–8237.00	406.43/222.13–2778.00	NS
TSLP	2.98/0–24.83	0/0–68.05	4.29/0–36.43	NS
LIF	9.16/4.68–26.63	7.54/0–46.49♦	12.59/7.58–27.43¶	<0.01
SDF-1α+β	1634.12 \pm 592.77¶	3225.83 \pm 923.98*♦	1383.92 \pm 787.63¶	<0.01
α-GRO	653.29/221.74–3966.00	594.85/215.69–1417.00	733.83/203.56–3747.00	NS
MCP-1	360.26 \pm 283.32	384.42 \pm 158.58	351.65 \pm 258.39	NS
MCP-2	24.63/13.10–68.63	24.98/16.98–45.63	25.03/14.99–88.91	NS
MCP-3	21.41/15.60–78.73	26.07/17.54–128.04	27.57/18.42–67.26	NS
MCP4	47.02/28.91–110.76¶	116.87/35.10–279.25*♦	47.94/25.09–314.91¶	<0.01
Fractalkine	59.15/41.68–198.57♦	58.94/45.90–302.91♦	127.07/56.35–402.24*¶	<0.01
Flt-3L	55.89/29.63–87.37	54.73/31.08–459.33	43.68/31.08–141.78	NS
ENA-78	468.77/88.65–4921.00	471.47/105.78–2515.00	446.81/54.94–8428.00	NS
TARC	26.89/3.25–278.16	24.93/4.49–111.62	16.16/4.25–388.75	NS
6CKine	363.59/225.31–1065.00¶	546.74/247.26–976.26*♦	342.75/262.83–729.32¶	<0.01
CCL1	4.91/4.10–12.72	5.48/3.59–34.86	5.53/4.29–11.65	NS
CCL22	643.34 \pm 273.73	561.68 \pm 204.79	511.75 \pm 345.07	NS
sCD30	17.49/0 – 99.00¶	371.89/30.16 – 993.99*♦	22.87/7.61 – 218.44¶	<0.01
sgp130	78160/42801 – 100000¶	274510/46460–1210000*♦	78518.83/0 – 100000¶	<0.01
sRAGE	237.62/32.12 – 788.06	1388.95/145.39 – 6253.66*	1474.33/187.76 – 3950.32*	<0.01

Legend: 6CKine: chemokine with 6 cysteines; α -GRO: α -oncogene related growth; BCA-1: B-cell chemokine attracting 1; CTACK: cutaneous T-cell attracting chemokine; EGF:

epidermal growth factor; ENA-78: epithelial neutrophil activating peptide 78; FGF: fibroblast growth factor; Flt-3L: FMS-like tyrosine kinase 3 ligand; G-CSF: granulocytes colonies stimulating factor; IL1Ra: IL1 receptor antagonist; IP10: IFN γ -induced protein 10; LIF: leukemia inhibitor factor; MCP: monocyte chemotactic protein; MIP1: macrophage inflammatory protein 1; PDGF: platelet-derived growth factor; RANTES: regulated on activation, normal T cell expressed and secreted; SCF: stem cell factor; SDF-1 α + β : stromal cell-derived factor 1 α and 1 β ; sIL1-R: soluble IL1 receptor; sIL2-R α : soluble IL2 receptor α ; sIL4-R: soluble IL4 receptor; sIL6-R: soluble IL6 receptor; sgp130: soluble glycoprotein 130; sRAGE: soluble receptor of advanced glycosylation end product; sTNFR: soluble TNF receptor; sVEGFR: soluble vascular endothelial growth factor receptor; TARC: thymus and activation-related chemokine; TNF: tumor necrosis factor; IFN: interferon; TRAIL: TNF-related apoptosis-inducing ligand; TSLP: thymic stromal lymphopoietin.

^a Data are expressed as median/minimum-maximum or mean \pm standard-deviation, according to normality.

Statistical analysis: Kruskal-Wallis test (post-test: Mann-Whitney) or one-way ANOVA (post-test: Buonferroni) when appropriated.

* p<0.05 compared to HC.

¶ p<0.05 compared to iBD.

◆ p<0.05 compared to aBD.